JP2008534520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008534520A5 JP2008534520A5 JP2008503326A JP2008503326A JP2008534520A5 JP 2008534520 A5 JP2008534520 A5 JP 2008534520A5 JP 2008503326 A JP2008503326 A JP 2008503326A JP 2008503326 A JP2008503326 A JP 2008503326A JP 2008534520 A5 JP2008534520 A5 JP 2008534520A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- dioclein
- floranol
- composition according
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- XZNFAYXFFDZGJD-AZUAARDMSA-N (2r,3r)-3,5,7-trihydroxy-2-(2-hydroxyphenyl)-6-methoxy-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one Chemical compound C1([C@H]2OC3=C(CC=C(C)C)C(O)=C(C(=C3C(=O)[C@@H]2O)O)OC)=CC=CC=C1O XZNFAYXFFDZGJD-AZUAARDMSA-N 0.000 claims 7
- LJTSNTOXRSAZNS-LBPRGKRZSA-N (2s)-2-(2,5-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-2,3-dihydrochromen-4-one Chemical compound C1([C@H]2OC=3C=C(C(=C(O)C=3C(=O)C2)OC)OC)=CC(O)=CC=C1O LJTSNTOXRSAZNS-LBPRGKRZSA-N 0.000 claims 7
- LJTSNTOXRSAZNS-UHFFFAOYSA-N Dioclein Natural products C1C(=O)C=2C(O)=C(OC)C(OC)=CC=2OC1C1=CC(O)=CC=C1O LJTSNTOXRSAZNS-UHFFFAOYSA-N 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- XZNFAYXFFDZGJD-UHFFFAOYSA-N floranol Natural products OC1C(=O)C2=C(O)C(OC)=C(O)C(CC=C(C)C)=C2OC1C1=CC=CC=C1O XZNFAYXFFDZGJD-UHFFFAOYSA-N 0.000 claims 5
- 239000000839 emulsion Substances 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 claims 3
- 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 claims 3
- 101150098694 PDE5A gene Proteins 0.000 claims 3
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 claims 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims 2
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims 2
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 claims 2
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 2
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 claims 2
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 claims 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 2
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 claims 2
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 claims 2
- 229940124639 Selective inhibitor Drugs 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 210000001367 artery Anatomy 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 230000003389 potentiating effect Effects 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- 230000000304 vasodilatating effect Effects 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229930003935 flavonoid Natural products 0.000 claims 1
- 150000002215 flavonoids Chemical class 0.000 claims 1
- 235000017173 flavonoids Nutrition 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
- 239000012074 organic phase Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0502411-0A BRPI0502411A (pt) | 2005-03-31 | 2005-03-31 | processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados |
| PCT/BR2006/000060 WO2006102728A2 (en) | 2005-03-31 | 2006-03-30 | Inclusion compounds of dioclein, floranol or analogs with cyclodextrin and their use for treating cardiovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008534520A JP2008534520A (ja) | 2008-08-28 |
| JP2008534520A5 true JP2008534520A5 (cg-RX-API-DMAC10.html) | 2009-05-14 |
Family
ID=37053732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503326A Pending JP2008534520A (ja) | 2005-03-31 | 2006-03-30 | ジオクレイン、フロラノール又は類似体ベースの、ホスホジエステラーゼのタイプ１から５のアイソフォーム（ｐｄｅ１、ｐｄｅ２、ｐｄｅ３、ｐｄｅ４、ｐｄｅ５）の強力で選択的な阻害剤としての薬物を開発する方法並びに心血管疾患の研究及び治療のためのそれらの医薬組成物及び関連製品 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090270495A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1877049A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2008534520A (cg-RX-API-DMAC10.html) |
| BR (1) | BRPI0502411A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2006102728A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0800596A2 (pt) * | 2008-01-31 | 2009-09-22 | Univ Minas Gerais | método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer |
| WO2010042633A2 (en) * | 2008-10-08 | 2010-04-15 | The General Hospital Corporation | Naringenin complexes and methods of use thereof |
| TW201036624A (en) * | 2009-03-27 | 2010-10-16 | Biotropics Malaysia Berhad | Aurones as selective PDE inhibitors and their use in neurological conditions and disorders |
| WO2012101618A1 (en) | 2011-01-28 | 2012-08-02 | Barcelcom Têxteis S.A. | Compression stockings and tubes with bioactive agents for the treatment of venous insufficiency and varicose veins |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| CN102988279B (zh) * | 2011-09-08 | 2016-06-15 | 石药集团中奇制药技术（石家庄）有限公司 | 松属素环糊精超分子包合物及其制备方法 |
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| EP3156405A1 (en) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9722520D0 (en) * | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| JP4390441B2 (ja) * | 2001-11-13 | 2009-12-24 | 武田薬品工業株式会社 | 抗癌剤 |
| GB0214784D0 (en) * | 2002-06-26 | 2002-08-07 | Pfizer Ltd | Novel combination |
| SE0202019D0 (sv) * | 2002-06-28 | 2002-06-28 | Abb As | Revalidation of a compiler for safety control |
-
2005
- 2005-03-31 BR BRPI0502411-0A patent/BRPI0502411A/pt not_active Application Discontinuation
-
2006
- 2006-03-30 US US11/887,564 patent/US20090270495A1/en not_active Abandoned
- 2006-03-30 WO PCT/BR2006/000060 patent/WO2006102728A2/en not_active Ceased
- 2006-03-30 EP EP06721619A patent/EP1877049A2/en not_active Withdrawn
- 2006-03-30 JP JP2008503326A patent/JP2008534520A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW562674B (en) | Compositions for treating or preventing inflammatory diseases | |
| KR102495941B1 (ko) | 신규한 방법 | |
| WO2024189607A1 (en) | Methods and bioavailable highly permeable compounds for diseases treatment | |
| Mohammadzadeh et al. | Promoting osteogenesis and bone regeneration employing icariin-loaded nanoplatforms | |
| US20040001871A1 (en) | Lapachone delivery systems, compositions and uses related thereto | |
| JP2011516428A5 (cg-RX-API-DMAC10.html) | ||
| JP6262225B2 (ja) | オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類 | |
| TW201811798A (zh) | sGC 刺激劑 | |
| JP2003525200A (ja) | ポリメラーゼ阻害剤としてのジケト酸誘導体 | |
| TW201004619A (en) | Methods and compositions for therapeutic treatment | |
| CN120091810A (zh) | 用于治疗病毒性疾病的方法和生物利用度高渗透性化合物 | |
| JP2016527308A (ja) | エンテカビル微小球及びこれを含む非経口投与用医薬組成物 | |
| WO2003004024A1 (en) | Injectable sustained-release microspheres of huperzine a compounds | |
| JP2022130689A (ja) | Ｓｇｃ刺激剤の固体形態 | |
| JP2003306481A5 (cg-RX-API-DMAC10.html) | ||
| US9987329B2 (en) | Methods for treating peripheral nerve damage | |
| KR20180071276A (ko) | Hcv 치료를 위한 조합물 요법 투약법 | |
| JP2022534427A (ja) | カスパーゼ阻害剤プロドラッグを含有する注射用組成物及びその調製方法 | |
| KR20090053218A (ko) | 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법 | |
| CN106164059A (zh) | 用天冬酰胺内肽酶（aep）抑制剂以及相关组合物对神经退行性疾病的治疗 | |
| ES2878579T3 (es) | Compuesto de fenol y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina, para el tratamiento de enfermedades de los sistemas nerviosos central y vascular | |
| CN101917988A (zh) | 用于治疗和预防心脏病的药物组合物 | |
| TW202038910A (zh) | 納曲酮注射型緩釋製劑 | |
| CN100423719C (zh) | 一种多烯紫杉醇纳米粒及其制备方法 | |
| Yan et al. | Comprehensive summary supporting clinical investigation of GS-441524 for Covid-19 treatment |